Biofortuna appoints new Chairman

Wirral-based molecular diagnostics company Biofortuna has appointed a new chairman to lead the next phase of growth.

Life sciences expert Ian Johnson will take on the role at Biofortuna, which specialises in freeze-dried diagnostics and contract services, with previous chairman Mark Hurley remaining on the board as a non-executive director.

Johnson has spent his career in the life sciences sector. He was previously founder and chief executive of Biotrace International, and he is currently non-executive chairman of Celsis Group and Cyprotex.

Biofortuna recently announced a £1.5m funding round to further develop its diagnostic assays and invest in its freeze-drying product capability. The £1.5m funding was supported by all of the company's current investors, including Foresight venture capital trusts, Catapult Ventures, Enterprise Ventures, the Merseyside Special Investment Fund, private investors and management.

Johnson said: "I am sure the board would join me in thanking Mark for his stewardship to date and I look forward to building on his achievements as the company commences a new phase of development."

Dr Simon Douglas, Biofortuna chief executive, said: "I am delighted to welcome Ian as the chairman. His significant experience and successful biotech track record will be invaluable for the company. The board, management team and I look forward to working with him."